Treatment of severe sepsis in patients with highly elevated IL-6 levels with anti-TNF monoclonal antibody MAK 195F: The Ramses study

被引：0
|
作者：
K Reinhart
机构：
[1] Friedrich-Schiller-University,Department of Anesthesiology
来源：
Critical Care | / 2卷 / Suppl 1期
关键词：
Severe Sepsis; High Mortality Risk; Randomise Patient; Receive Placebo; Plan Interim Analysis;
D O I：
10.1186/cc148
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 36 条
  • [1] Anti-TNF treatment of baboons with sepsis reduces TNF-α, IL-6 and IL-8, but not the degree of complement activation
    Bengtsson, A
    Redl, H
    Schlag, G
    Högåsen, K
    Götze, O
    Mollnes, TE
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1998, 48 (05) : 509 - 514
  • [2] Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study
    Reinhart, K
    WiegandLohnert, C
    Grimminger, F
    Kaul, M
    Withington, S
    Treacher, D
    Eckart, J
    Willatts, S
    Bouza, C
    Krausch, D
    Stockenhuber, F
    Eiselstein, J
    Daum, L
    Kempeni, J
    CRITICAL CARE MEDICINE, 1996, 24 (05) : 733 - 742
  • [3] Circulating levels of plasma IL-6, VEGF, YKL-40, and COMP in spondyloarthritis patients during anti-TNFα treatment
    Pedersen, Susanne Juhl
    Sorensen, Inge Juul
    Johansen, Julia Sidenius
    Madsen, Ole Rintek
    Tvede, Niels
    Hansen, Michael Sejer
    Thamsborg, Gorm
    Andersen, Lis Smedegaard
    Majgaard, Ole
    Loft, Anne Gitte
    Erlendsson, Jon
    Asmussen, Karsten
    Hansen, Annette
    Ostergaard, Mikkel
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2008, 37 : 38 - 38
  • [4] Prospective multicenter study of the effect of early fluid resuscitation on trends in IL-6 and TNFα levels in severe sepsis
    R Arnold
    A Jones
    N Shapiro
    S Trzeciak
    RP Dellinger
    Critical Care, 14 (Suppl 2):
  • [5] EFFECT OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR (TNF MAB) ON TNF-ALPHA, IL-1-BETA AND IL-6 LEVELS IN PATIENTS WITH SEPSIS SYNDROME
    CHOW, AW
    TWEEDDALE, MG
    SLEIGH, K
    POONIA, K
    MERKS, H
    CLINICAL RESEARCH, 1994, 42 (02): : A299 - A299
  • [6] Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study (vol 24, pg 733, 1996)
    Reinhart, K
    CRITICAL CARE MEDICINE, 1996, 24 (09) : 1608 - 1608
  • [7] Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? a multicentre retrospective observational study
    Fernando Kemta Lekpa
    Cécile Poulain
    Daniel Wendling
    Martin Soubrier
    Michel De Bandt
    Jean Marie Berthelot
    Philippe Gaudin
    Eric Toussirot
    Philippe Goupille
    Thao Pham
    Jérémie Sellam
    Rémy Bruckert
    Muriel Paul
    Valérie Farrenq
    Pascal Claudepierre
    Arthritis Research & Therapy, 14
  • [8] Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? a multicentre retrospective observational study
    Lekpa, Fernando Kemta
    Poulain, Cecile
    Wendling, Daniel
    Soubrier, Martin
    De Bandt, Michel
    Berthelot, Jean Marie
    Gaudin, Philippe
    Toussirot, Eric
    Goupille, Philippe
    Thao Pham
    Sellam, Jeremie
    Bruckert, Remy
    Paul, Muriel
    Farrenq, Valerie
    Claudepierre, Pascal
    ARTHRITIS RESEARCH & THERAPY, 2012, 14 (02)
  • [9] An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients
    Saavedra, Danay
    Ane-Kouri, Ana Laura
    Sanchez, Naivy
    Filgueira, Lazaro Manuel
    Betancourt, Julio
    Herrera, Carlos
    Manso, Leniel
    Chavez, Elibet
    Caballero, Armando
    Hidalgo, Carlos
    Lorenzo, Geydi
    Cepeda, Meylan
    Valenzuela, Carmen
    Ramos, Mayra
    Leon, Kalet
    Mazorra, Zaima
    Crombet, Tania
    IMMUNITY & AGEING, 2020, 17 (01)
  • [10] An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients
    Danay Saavedra
    Ana Laura Añé-Kourí
    Naivy Sánchez
    Lázaro Manuel Filgueira
    Julio Betancourt
    Carlos Herrera
    Leniel Manso
    Elibet Chávez
    Armando Caballero
    Carlos Hidalgo
    Geydi Lorenzo
    Meylan Cepeda
    Carmen Valenzuela
    Mayra Ramos
    Kalet León
    Zaima Mazorra
    Tania Crombet
    Immunity & Ageing, 17
1234